Sun, Feb 1, 2015, 8:59 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • scanit2008 scanit2008 Mar 28, 2013 8:41 AM Flag

    Motley Fool Choses Arena / Belviq

    The battle between all the obesity drug makers will take a while to pan out and see which drug gains more market share. But overall, I think that Arena Pharmaceuticals will be the top seller against Qsymia, because of its safety profile.

    For Orexigen it is still up in the air, because they won't go up against an FDA panel for approval until 2014. Also we don't know if the "Light Study" from Orexigen will be enough to show the FDA that Contrave is safe and effective. Qsymia has started earlier in sales for now, and it still remains to be seen how successful it will be in the long run.

    Arena pharmaceuticals is set to bring out Belviq sometime in 2013, and it should sell well because of its safety profile. If I had to choose one winner out of all the obesity drugs, I would choose Arena's Belviq for long-term success.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARNA
4.31-0.200(-4.43%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.